Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation

Nurix anticipates nominating a clinical candidate within the first year of the extension

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6). STAT6 is a key drug target in type 2 inflammation.

“STAT6 is a key transcription factor within the IL-4/IL-13 signaling pathways which act as drivers of inflammation in allergic conditions. These conditions are currently treated with injectable monoclonal antibody therapies, which are designed to impede IL-4/IL-13 signaling,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “Preclinical data from our STAT6 degraders show that targeted degradation of this key transcription factor provides a rapidly acting and potent blockade of signaling. We anticipate nominating a clinical candidate from this advanced preclinical program in the coming twelve months.”

“The extension of the STAT6 research program with Sanofi speaks to the success of our current collaboration which combines Nurix’s leadership in the design and development of targeted protein degraders with Sanofi’s industry-leading expertise and capabilities in inflammation and immunology,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “We are very excited to pursue our collaboration with Sanofi, as it further demonstrates the productivity of our long-standing research program to develop a pipeline of breakthrough degraders to treat inflammation and autoimmunity. Nurix’s disclosed pipeline in inflammation and autoimmunity now includes the STAT6 degrader with Sanofi, the IRAK4 degrader with Gilead, and Nurix’s proprietary BTK degrader, NX-5948. We look forward to continuing to work with the Sanofi team to advance this exciting STAT6 program to bring new therapeutic options to patients.”